EUVIMEDOtkrijte EUVIMED
Crossref

Outcomes of heart transplant recipients bridged with percutaneous versus durable left ventricular assist devices

Yu Xia, Juka S Kim iD, Isabel K Eng, Ali Nsair, Abbas Ardehali, Richard J Shemin, Murray H Kwon

Clinical Transplantation · 2023-04 · 37 (4)

DOI: 10.1111/ctr.14904 ↗

At a glance

Journal article in Clinical Transplantation, published online on 2023-02-07. Written by Yu Xia and 6 co-authors. Institution: Division of Cardiac Surgery, Department of Surgery, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California, U…. Major MEDLINE topics: Heart Transplantation, Heart-Assist Devices, Heart Failure. Cited 6 times so far (Crossref); 23 references.

SažetakSubjectsBibliografski podaciCiteRelated studies

Abstract (original language)

Background

The new United Network for Organ Sharing (UNOS) heart allocation policy prioritizes temporary percutaneous over durable left ventricular assist devices (LVAD) as bridge to transplant. We sought to examine 1‐year outcomes of heart transplant recipients bridged with Impella versus durable LVADs.

Methods

All primary adult orthotopic heart transplant recipients registered in UNOS between January 2016 and June 2021 were analyzed. Recipients were identified as being bridged with isolated durable or percutaneous LVAD at the time of transplant. Baseline characteristics were compared and 1‐year survival was examined using the Kaplan Meier method and multivariable Cox proportional hazards regression.

Results

During our study period, heart transplant recipients bridged with LVADs were divided between 5422(94%) durable and 324(6%) percutaneous options. Impella‐bridged recipients were more likely to be status 1A under the old allocation system (98% vs. 70%, p < .01) and status 2 or higher under the new allocation system (99% vs. 24%, p < .01). Impella‐bridged recipients were less likely to be obese (27% vs. 42%, p < .01), have ischemic cardiomyopathy (27% vs. 34%, p < .01), and were more likely to be on inotropic agents at the time of transplant (68% vs. 6%, p < .01). One‐year post‐transplant survival was not significantly different between the two groups on univariable (HR .87, 95% CI .56–1.37) or multivariable analysis (aHR .63, 95% CI .37–1.07).

Conclusions

Following the UNOS allocation policy change, Impella utilization has increased with no significant difference in 1‐year survival compared to bridge with durable LVADs. Impella may be a reasonable alternative to durable LVADs in select patients.

Subjects

MeSH terms (MEDLINE)

Heart TransplantationHeart-Assist DevicesHeart FailureAdultHumansTreatment OutcomeGraft SurvivalRetrospective Studies

Author keywords

ImpellaLVADheart transplant

Authors and institutions

  • Division of Cardiac Surgery, Department of Surgery, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California, USA.
  • Department of Medicine, Division of Cardiology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, California, USA.

ORCID profiles: Juka S Kim

Cite

APA

Xia, Y., Kim, J. S., Eng, I. K., Nsair, A., Ardehali, A., Shemin, R. J., & Kwon, M. H. (2023). Outcomes of heart transplant recipients bridged with percutaneous versus durable left ventricular assist devices. Clinical Transplantation, 37(4). https://doi.org/10.1111/ctr.14904

Vancouver

Xia Y, Kim JS, Eng IK, Nsair A, Ardehali A, Shemin RJ, et al. Outcomes of heart transplant recipients bridged with percutaneous versus durable left ventricular assist devices. Clinical Transplantation. 2023;37(4). doi:10.1111/ctr.14904

BibTeX
@article{Xia2023,
  author = {Xia, Yu and Kim, Juka S and Eng, Isabel K and Nsair, Ali and Ardehali, Abbas and Shemin, Richard J and Kwon, Murray H},
  title = {Outcomes of heart transplant recipients bridged with percutaneous versus durable left ventricular assist devices},
  journal = {Clinical Transplantation},
  year = {2023},
  volume = {37},
  number = {4},
  doi = {10.1111/ctr.14904}
}
Start for free →